Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $23.64
Previous CloseN/A
Volume407.39K
Average Volume (3M)2.97M
Market Cap
$4.80B
Enterprise Value$4.20B
Total Cash (Recent Filing)$22.75M
Total Debt (Recent Filing)$44.22M
Price to Earnings (P/E)25.0
Beta1.04
Next Earnings
May 07, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding237,615,100
10 Day Avg. Volume3,879,206
30 Day Avg. Volume2,971,242
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.03
Price to Cash Flow (P/CF)23.40
P/FCF Ratio23.40
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit47.18
Enterprise Value/Ebitda42.61
Forecast
1Y Price Target
$25.00Price Target Upside26.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADMA's underlying performance is strong, as evidenced by improved guidance for 2025 and 2026 following their earnings report.
Production And SalesThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.
Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.
Bears Say
Guidance ConcernsA more modest than expected 2025 guide contributed to uncertainty in the market.
Market ReactionsKey triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.
Regulatory ChallengesADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.
---
Ownership Overview
3.30% Insiders
21.19% Mutual Funds
13.15% Other Institutional Investors
34.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $5.89 and its highest was $23.64 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $4.80B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is May 07, 2025 which is in 41 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Mar 03, 2025. The company reported $0.141 earnings per share for the quarter, missing the consensus estimate of $0.15 by -$0.009.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.16.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 237,615,100 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.141 in its last earnings report, missing expectations of $0.15. Following the earnings report the stock price went up 7.454%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
---
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (26.90% Upside)
$25.00 (26.90% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
216.43%
12-Months-Change
Fundamentals
Return on Equity
81.65%
Trailing 12-Months
Asset Growth
51.40%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
---
ADMA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook for ADMA Biologics, with significant revenue growth and strategic advancements in high-titer plasma supply and ASCENIV's market potential. However, there is some uncertainty with pending FDA approval and delayed audit completion.Read More>---
ADMA Stock 12 Month Forecast
Average Price Target
$25.00
▲(26.90% Upside)
Technical Analysis
Best Analysts Covering ADMA
1 Year
1 Year Success Rate
19/25 ratings generated profit
1 Year Average Return
+79.98%
reiterated a buy rating 9 days ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +79.98% per trade.
---